HCW Biologics highlights TGF-β trap and IL-15 fusion immunotherapy approach
HCW Biologics says its TGF-β trap and IL-15 fusion platform is a novel moiety intended to enhance immunotherapeutic activity against diseased cells.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.